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Background: The objective of this clinical open-label trial was to test the safety, tolerability and efficacy of IGF-1
therapy for autosomal dominant cerebellar ataxia (ADCA) patients.
Results: A total of 19 molecularly confirmed patients with SCA3, 1 patient with SCA6 and 6 patients with SCA7
completed our study. They were 8 females and 18 males, 28 to 74 years of age (average ± SD: 49.3 ± 14.1). Patients
were treated with IGF-1 therapy with a dosage of 50 μg/kg twice a day for 12 months. The efficacy of this therapy
was assessed by change from baseline on the scale for the assessment and rating of ataxia (SARA). Ten patients,
consecutively selected, continued their assigned dosages in a second year open-label extension trial. A statistically
significant improvement in SARA scores was observed for patients with SCA3, patients with SCA7 and all patients
grouped together after the first year of IGF-1 therapy, while a stabilization of the disease was confirmed during the
second year (extension study). The single patient with SCA6 showed 3 improvement points in SARA score after 3
four-month periods of IGF-1 therapy when compared with baseline measurements. Our data indicate that IGF-1 is
safe and well tolerated in general.
Conclusions: Our data, in comparison with results from previous cohorts, indicate a trend for IGF-1 treatment to
stabilize the disease progression for patients with SCA, indicating that IGF-1 therapy is able to decrease the progressivity
of ADCA.
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The discovery of nerve growth factor by Levi-Montalcini
and Cohen in 1956 [1] strongly supported the concept
that secreted molecules produced by a developing neuron
are required for it to survive programmed cell death
(apoptosis). Apoptosis is high during embryonic develop-
ment, during which roughly half of the developing post-
mitotic neurons die.
Neurotrophic factors rescue neurons from apoptosis
by blocking cell death programs in some physiological
contexts. However, neurotrophic factor protection is
sometimes limited by pharmacokinetic constraints in
well − defined diseases (such as Alzheimer disease and
Parkinson’s disease) [2,3].* Correspondence: jarpag@ctv.es
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article, unless otherwise stated.The insulin-like growth factor system plays important
metabolic, trophic and modulatory functions in the cen-
tral nervous system, increasing cell proliferation, survival
and anti-apoptotic responses [4-6]. Central and periph-
eral insulin-like peptides including insulin, insulin-like
growth factor 1 (IGF-1), and IGF-2 exert many effects
on the brain cells. They are abundant circulating neuro-
protective hormones that might be involved with the
control of energy allocation [7]. Disrupted IGF-1 neuro-
protective signalling might therefore constitute a com-
mon stage in the pathological cascade associated with
neuronal death. Second to disease-specific mutations,
dysregulation of the IGF-1 signalling pathway is a recur-
rent finding in mouse models for cerebellar ataxia. The
IGF-1 signalling pathway thus represents a common
pathological cascade for neuronal cell death that might
be a potential therapeutic target. IGF-1 therapy seems to
be beneficial for different brain diseases, including vari-
ous types of cerebellar ataxia in animal models [8-12]
and human patients [13]. Whereas the general protectiveentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Sanz-Gallego et al. Cerebellum & Ataxias 2014, 1:13 Page 2 of 9
http://www.cerebellumandataxias.com/content/1/1/13actions of IGF-1 in the brain are well documented, the
disease-specific actions of IGF-1, if any, are not yet
known. There are several neurodegenerative conditions
with probable IGF-1 dysfunction [14]. For instance, two
spinocerebellar ataxia (SCA) mouse models (for SCA1
and SCA7) showed a down-regulation of insulin-like
growth factor binding protein 5 (Igfbp5) transcripts [15].
Two other ataxic diseases with a different aetiology and
pathology, ataxia-telangiectasia and Friedreich’s ataxia
(FRDA), might also show disturbed IGF-1 function [14].
Shahrabani-Gargir et al. [16] showed a significant reduc-
tion in basal IGF-1 receptor (IGF-1R) values, together
with an impaired IGF-1R response after DNA damage in
cells with deficient ataxia-telangiectasia mutated (ATM)
function [16]. FRDA shows excess oxidative stress that
provokes genotoxic DNA damage [17]. IGF-1 exerts
cell-context neuroprotection for frataxin deficiency that
might be therapeutically effective in FRDA. Both types
of ataxia show cumulative DNA damage [14].
The Insulin/IGF-1 signaling pathway contributes to
cell survival and glucagon like peptide-1(GLP-1) has
similar functions and growth like properties as insulin/
IGF-1. Dysfunction of these pathways seems to contrib-
ute to the progressive loss of neurons in Alzheimer’s
disease and Parkinson’s disease. These findings have led
to numerous studies in preclinical models of neurodegen-
erative disorders with currently available anti-diabetics
[18]. IGF-1 via activation of the serine/threonine kinase
Akt/PKB is able to inhibit neuronal death specifically
induced by mutant huntingtin containing an expanded
polyglutamine (polyQ) stretch [19]. In transgenic animal
models of polyQ disorders, there was also evidence
of the involvement of insulin/IGF-1 system (IIS) sig-
nalling components. IIS proteins were implicated in the
modulation of mutant proteins as well as in the disease
phenotype [20,21]. Abnormalities in the IIS signalling
pathway are also thought to play a part in the physiopath-
ological processes of various neurodegenerative disorders,
including Alzheimer’s disease, SCAs and Huntington
disease [4,5,22,23].
Our previous small sample clinical trial showed that a
subcutaneous dosage of human recombinant IGF-1 of
50 μg/kg twice a day stabilized SCA3 and SCA7 disease
progression during the study period [13]. In this paper
we added to the previous series the patients of a second
study, with the purpose of evaluating a possible increase
of the statistical power.
These findings led to make up of the open-label study
described here. The primary aim of this study was to
demonstrate the safety and tolerability of IGF-1 ther-
apy for patients with autosomal dominant cerebellar
ataxia (ADCA). The secondary objective was to evalu-
ate the efficacy of IGF-1 therapy for the treatment of
ADCA.Results
Patients
A total of 30 patients, 28 to 74 years of age (average ± SD:
49.3 ± 14.1), were included for this study in the beginning.
There were 20 molecularly confirmed patients with SCA3,
2 patient with SCA6 and 8 patients with SCA7. Patients
had a baseline SARA score [24] between 8 and 26.75
(average ± SD: 13.2 ± 5.4) (Table 1). Patients were treated
with IGF-1 (mecasermin, Increlex®; Ipsen-Pharma) therapy
with a dosage of 50 μg/kg twice a day for 12 months. The
efficacy of this therapy was assessed by change from base-
line on the scale for the assessment and rating of ataxia
(SARA) and SF-36v2 Health Survey [25] (see “Methods”
session below). Ten patients, consecutively selected, con-
tinued their assigned dosages in a second year open-label
extension trial.
Safety and tolerability
In general, IGF-1 was well tolerated by the patients with
ADCA. Vital signs showed no remarkable changes from
baseline. A total of 4 patients were unable to complete
the study: 1 patient with SCA7 died during the follow-
up because of aspiration pneumonia; 1 patient with
SCA3 withdrew voluntarily; 1 patient with SCA7 was
withdrawn because of consecutive fracture and fasting
hypoglycaemia; and 1 patient with SCA 6 withdrew be-
cause a traffic accident. Of the remaining patients, 2 pre-
sented common warts, 2 women gradually changed from
straight hair to curly hair and 1 woman showed an alter-
ation in the frequency and duration of her menstrual cycle.
Efficacy
26 patients, 8 females and 18 males, completed the
study. A significant improvement in SARA scores was
observed for all patients and the SCA3 and SCA7 sub-
groups after the first year of IGF-1 treatment (Figure 1).
On the Wilcoxon signed ranks test, the SARA score was
significantly lower after 1 year of IGF-1 treatment when
compared with baseline (p < 0.05). The single patient
with SCA6 showed 3 improvement points in SARA
score after 3 four-month periods of IGF-1 therapy when
compared with baseline measurements. The parameters
of SARA that more favorably have been influenced
(% score reduction average) by the IGF-1 therapy are
nose-finger test (−7.75%), heel-chin slide (−7.5%), stance
(−5.8%), gait (−4.25%), and finger chase (−3.25%). The
parameters that worse respond are fast alternating hand
movements (−0.32%), sitting (+0.5%), and speech disturb-
ance (+1.25%).
The annual worsening rate was estimated for this
series to be a SARA score of average ± SD: −1.68 ± 2.8
(95% CI: −2.77 to −0.59), whereas the annual worsening
rate for the Jacobi et al. SCA3 cohort [26] was esti-
mated to be a SARA score of average ± SD: 1.61 ± 0.12
Table 1 Demographic and clinical variables of the 26 study patients
Patients(N) Age (average ± SD) (rank) Gender (M/F,%) (N) Age at onset
(average ± SD) (rank)
Disease duration (years)
(average ± SD) (rank)
Expanded CAG repeats
(average ± SD) (rank)
Baseline SARA
(average ± SD) (rank)
SCA3 (19) 50.32 ± 13.60 (28 – 74) 68.4/31.6 (13/6) 40.53 ± 12.19 (20 – 62) 9.84 ± 7.41 (2 – 30) 47.3 ± 33.5 (52 – 75) 11.89 ± 4.82 (8 – 28)
SCA7 (6) 45.71 ± 16.86 (28 – 66) 71.4/28.6 (5/2) 34.71 ± 10.87 (23 – 48) 11.00 ± 6.02 (4 – 18) 43.3 ± 24.3 (34 – 50) 16.19 ± 6.32 (8–27)
SCA6 (1) 55 100/0 48 7 23 14
Total (26) 49.30 ± 14.12 (28–74) 70.37/29.63 (19/8) 39.3 ± 11.83 (20 – 62) 10.04 ± 6.92 (2 – 30) ─ 13.17 ± 5.38 (8 – 28)
N number.
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Figure 1 These charts with mean and standard deviation lines show four-monthly score changes from baseline on the scale for
the assessment and rating of ataxia (SARA) during the first year of treatment with IGF-1. A significant improvement in SARA scores
was observed for all patients (26) (top), and the SCA3 (19 patients) (middle), and SCA7 (6 patients) (bottom) subgroups after the first year of
IGF-1 treatment.
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average ± SD: 1.5 ± 0.9 (95% CI: 0.79 to 2.21) (Table 2).
Confidence interval calculated for the measure of treat-
ment effect is not included within the limits of upper and
lower bounds of the CI control, which would seem to in-
dicate a decrease in the progression of the disease with
IGF-1 therapy. The comparison of our results with those
of Jacobi et al. in SCA3 and SCA6 [18], and our own
SCA7 SARA score, indicated that our patients with
ADCA who receive IGF-1 treatment showed a stabilization
of disease progression.
Data from our extension study suggests that IGF-1
treatment might be effective for reducing the progres-
sion of SCAs long-term (Figure 2; Table 2). These results
must be interpreted under the limitations of the study
design. Although they suggest that IGF-1 has a beneficial
effect, full-fledged clinical trials are needed to prove that
such an effect exists.
SF-36v2
SF-36v2 scales showed that of the 26 patients, 18.5%
were dissatisfied, 14.8% had poor satisfaction, 37% had
fair satisfaction, and 29.6% showed high satisfaction dur-
ing the limited study duration.
Discussion
Exogenous trophic factors (such as glial derived neuro-
trophic factor and IGF-1) can delay the onset of heredi-
tary Purkinje cell degeneration and gait ataxia in shaker
mutant rats. These rats present spatially restricted de-
generation of cerebellar Purkinje neurons from adult-onset
heredodegeneration [11].
Serum levels of insulin, IGFs and IGF binding pro-
teins (IGFBPs) are altered in human neurodegenerative
diseases of various aetiologies, such as Alzheimer’s disease,
amyotrophic lateral sclerosis, and cerebellar ataxia [27].
Two types of late-onset cerebellar ataxias (olivoponto-
cerebellar and idiopathic cerebellar cortical atrophy)Table 2 Annual worsening rate estimated for this series
Patients N Annual worsening
index (average ± SD)
95% confidence
interval for mean
1 year−baseline SCA3 19 −1.54 ± 3.0 −2.89 −0.19
SCA7 6 −2.12 ± 2.1 −3.80 −0.44
SCA6 1 −3 −3 −3
2nd year
(extension)
SCA3 6 −0.08 ± 1.11 −0.97 0.81
SCA7 4 0.63 ± 1.93 −1.26 2.52
Control SCA3 139 1.61 ± 0.12 1.59 1.63
Control SCA7 7 1.5 ± 0.9 0.79 2.21
Control SCA6 107 0.35 ± 0.34 0.29 0.41
Comprehensive quantitative account of disease progression was given by
Jacobi et al. [26]. N number.show low IGF-I levels in the blood but high levels of
IGFBP-1 and IGFBP-3 [28].
Both ataxic animals and human patients with ataxia
show altered serum IGF-1 levels. The pathological sig-
nificance of this alteration, however, remains unknown.
That said treatment with IGF-I has proven effective
for neurotoxic and transgenic animal models of ataxia
[29-31]. Mouse models of SCA1 and SCA7 showed a
down-regulation of IGFBP-5 transcripts [15].
Serum levels of IGFs are also altered in two very dif-
ferent inherited neurodegenerative conditions, ataxia-
telangiectasia and Charcot-Marie-Tooth 1A disease. Both
types of patients have increased serum IGF-1 and IGFBP-2
levels, and decreased serum IGFBP-1 levels; while only
ataxia-telangiectasia patients have high serum insulin levels
[27]. Ataxia-telangiectasia and FRDA show cumulative
DNA damage and might also show disturbed IGF-1 func-
tion [14]. DNA damage is known to reduce IGF-1 activity
[32]. Altered serum levels of IGF-1 and IGFBPs have been
reported in patients with late onset cerebellar ataxia [28].
IGF-1 normalised frataxin levels in frataxin-deficient
neurons and astrocytes through the protein kinase
B/mechanistic target of rapamycin signalling pathway. Fur-
thermore, IGF-1 significantly increased levels of frataxin in
cardiomyocites from conditional FRDA mouse mutants.
These molecular improvements seen with IGF-1 also affect
behaviour; for example, IGF-1 normalised motor coordin-
ation in the moderately FRDA-like transgenic mice [14].
IGF-1 has therapeutic effects for various types of cere-
bellar ataxias [13], exerting protective actions on mito-
chondrial function. Beneficial effects were observed with
the use of IGF-1 therapy for FRDA patients. Participants
in this proof-of-concept trial showed neurological im-
provement as measured by SARA and SF-36v2 scales.
They also showed a decrease in neurological disease pro-
gression, together with possibly long-term stability of
cardiac function. These data seem to indicate that IGF-1
therapy holds certain neurological and possibly cardiac
benefits for patients with FRDA [Sanz-Gallego et al.,
Cerebellum & Ataxias 2014, 1:10].
IGF-1 treatment has been tested in clinical trials for
various disorders [13,33-36] and, with the exception
of early clinical studies (that utilised very high doses of
IGF-1 inducing transient hypoglycaemia), no significant
adverse effects have been reported. In the present series,
1 patient with SCA7 was withdrawn because of consecu-
tive fracture and fasting hypoglycaemia, 2 subjects pre-
sented common warts, 2 women gradually changed from
straight hair to curly hair, and 1 woman showed an alter-
ation in the frequency and duration of her menstrual
cycle. In general, IGF-1 therapy was well tolerated by our
patients with ADCA.
We have considered including only patients with
SARA score between 8 and 28. So, the subject affection
Figure 2 These charts with mean and standard deviation lines show four-monthly score changes from baseline on the scale for
the assessment and rating of ataxia (SARA) during two years of treatment with IGF-1. Data from this extension study suggests that
IGF-1 treatment might be effective for reducing the progression of SCAs long-term: Total number of patients (10) (top), SCA3 (6 patients)
(middle), and SCA 7 (4 patients) (bottom) subgroups.
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the patient can be assessed by means all items of the
SARA scale (for example, gait and stance).In the present study, we have included analysis and
comparisons with previous data of Jacobi et al. work
(26). This study provides a quantitative account of the
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SCA3, and SCA6). It is based on an analysis of the first
2 years of the ongoing EUROSCA natural history study,
a multicentric longitudinal cohort study of 526 patients.
The advantages of this study are its prospective nature
and the use of validated clinical scales (SARA). All pa-
tients had moderate disease severity. We consider that
our patient’s characteristics resemble closely that cohort.
The comparison of our results with those of Jacobi et al.
in SCA3 and SCA6 [26], and our own SCA7 SARA
score, indicated that our patients with ADCA who re-
ceive IGF-1 treatment showed a stabilization of disease
progression. Data from our extension study suggests that
IGF-1 treatment could be effective for reducing the pro-
gression of some SCAs long-term.
There exist limitations of this study. This was an
open-label study, with a limited number of valid patients
[11], a probable significant initial placebo effect, and a
baseline score variability that influenced each individual’s
evolution. We did not include placebo group and the
number of extension study patients was limited to 10
due to budget restrictions.
Conclusions
IGF-1 therapy was generally well tolerated by our pa-
tients with ADCA. The comparison of our data with that
from a previous cohort indicates that IGF-1 treatment
for patients with ADCA stabilizes disease development.
This observation also suggests that IGF-1 therapy is able
to decrease further progression of ADCA.
Further studies with more patients and double-blind
placebo-controlled studies are necessary to more defini-
tively assess the effectiveness of IGF-1 therapy. In the
future, IGF-1 dosing might be changed from the con-
ventional twice a day to once every 2 weeks by means
of IGF-1 microsphere therapy [37].
Methods
All participants provided written informed consent to par-
ticipate in this open-label trial approved by the Institutional
Ethical Committee of Clinical Research.
Study design and end-points
We conducted a 1-year prospective open-label pilot clin-
ical trial for patients with SCA3, SCA6, and SCA7 using
2-daily subcutaneous administrations of recombinant
human IGF-1. A total of 27 out of the 30 initially re-
cruited patients were considered valid for this study,
and 26 patients completed it. Patients were recruited from
the Unit of Hereditary Ataxia and Spastic Paraplegia at
Hospital Universitario La Paz (Madrid, Spain). Subjects
were required to have a SARA score between 8 and 28.
Demographic and clinical variables of the 27 study patients
are shown in Table 1. Baseline clinical characteristics wererecorded including age, gender, height, weight, blood pres-
sure, medical history and medications. Exclusion criteria
were as follows: history of malignancy, active renal disease
or other systemic illnesses that would make participation
unsafe, diabetes mellitus or active major depression, the
use of any investigational drugs within the previous 30 days,
the inability to comply with requirements of the protocol;
pregnancy, breastfeeding or planning to become pregnant
during the study period.
The primary outcomes were safety concerns. The sec-
ondary outcome was the change at 4, 8 and 12 months
in neurological symptoms measured with the scale for
the assessment and rating of ataxia (SARA) [24] com-
pared with the baseline for each type of SCA and SF-36v2
scores [25]. This change was also evaluated for the com-
posite of all SCAs, as a single group.
Patients who consecutively completed this pilot clin-
ical trial were presented the option to continue IGF-1
therapy in an open-label, single treatment, safety and ef-
ficacy, long-term extension study for a period of 1 year.
A total of 12 patients, consecutively selected, were en-
rolled for this extension study, and 10 patients com-
pleted it.
IGF-1 treatment
The intervention consisted of a subcutaneous injection
of recombinant human IGF-1 (mecasermin, Increlex®;
Ipsen-Pharma). A dose of 0.50 μg/kg body weight of IGF-1
was subcutaneously injected twice daily. This represented
the highest tolerated dose in phase I human dose escal-
ation studies, with hepatic toxicity being the dose limiting
factor [38,39].
Clinical evaluation
Safety assessments included:
1. Haematology assessments (consisting of haemoglobin,
total and differential white blood cell count, absolute
neutrophil count and platelet count) at baseline,
every 4 months (±7 days) during the study, and at
the end of the study or early termination, whichever
came first.
2. Blood chemistry assessments (consisting of fasting
glucose, alanine aminotransferase, aspartate
aminotransferase, and creatinine) at baseline, every
4 months (±7 days), and at the end of the study or
early termination, whichever came first.
3. Physical examination (including head, eyes, ears, nose,
throat, cardiovascular, respiratory, musculoskeletal,
dermatological, neurological, lymph nodes, endocrine/
metabolic, gastrointestinal, genitourinary and
reproductive examinations) at baseline, and at the
end of the study or early termination, whichever
came first.
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temperature) at baseline, every 4 months (±7 days)
and at the end of the study, or early termination,
whichever came first.
5. Electrocardiogram: at baseline, 12 months (±7 days)
after start of the study, and at the end of the study
or early termination, whichever came first.
6. Adverse events and medication(s): subjects were
questioned about the occurrence of any adverse
events and the use of any medication(s) at baseline,
every 4 months (±7 days) during the study and at
the end of the study (or early termination).
7. Urine pregnancy tests were performed at baseline,
every 4 months (±7 days) and at the end of the
study (or early termination) for all females of
childbearing potential. Contraceptive counselling
was also provided for all sexually active females.
Efficacy analysis
Periodic functional analyses were conducted with SARA
every 4 months (±7 days), and at the end of the study or
early termination, whichever came first. Patient satisfaction
with IGF-1 therapy was measured using the SF-36v2. This
scale is a validated and widely used quality-of-life measure-
ment originating from the Medical Outcomes Study. The
survey consists of 36 multiple-choice health-related ques-
tions, grouped into eight multi-item domains measuring
quality in different aspects of daily life (25). SF-36v2 is
included in our Clinical Pathway of Degenerative Ataxias
and Spastic Paraplegias.
Statistical analysis
Safety analyses were performed on the safety intent-to-
treat population, which was defined as selected patients
who were administered at least one dose of the allocated
drugs. Efficacy analyses were performed on the per
protocol population, which was defined as those patients
who had completed at least one 4-month period in the
study and who had no major protocol violations.
For the efficacy assessments, the change from baseline
to every 4 months and the end of the study was calcu-
lated. Non-parametric Wilcoxon-Mann–Whitney test
were used to compare the change from baseline to post-
baseline visits for all efficacy parameters. The evolution
in time was studied (quarterly) using linear mixed-
effects models for the adjustment of correlations caused
by repeated measurements made on the same statistical
units (longitudinal study). The aim was to determine the
quarterly rate of change with a confidence interval (CI)
of 95%. In 2011, a study performed on 139 patients with
SCA3 reported that the mean SARA 1-year worsening of
the cohort was 1.61 ± 0.12 (average ± SD) points. In this
study, SARA progression in SCA6 (107 patients) was
slowest and nonlinear (first year average ± SD: 0.35 ± 0.34,second year: 1.44 ± 0.34) [26]. These data were used for
the comparison of our results. In case of SCA7 the annual
worsening index matches our own patients’ annual wors-
ening index prior to the beginning of the trial, with mean
SARA 1-year worsening of the cohort was 1.5 ± 0.9
(average ± SD) points.
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